GeoVax Labs, Inc. announced the completion of an interim data review by the Data Safety Monitoring Board for the ongoing Phase II clinical trial of GEO-CM04S1, GeoVax’s dual-antigen next-generation COVID-19 vaccine, as a booster vaccine for patients with chronic lymphocytic leukemia.
[GeoVax Labs, Inc.]
